JERUSALEM, Israel — Teva Pharmaceuticals on Wednesday introduced generic Pristiq (desvenlafaxine) extended-release tablets, 25, 50 and 100 mg, in the United States.
Desvenlafaxine extended-release tablets, a SNRI, are indicated for the treatment of major depressive disorder. The efficacy of desvenlafaxine extended-release tablets has been established in four short-term (8-week, placebo-controlled studies) and two maintenance studies in adult outpatients who met DSM-IV criteria for MDD.
Pristiq had annual sales of approximately $883 million in the U.S. according to IMS data as of December 2016.
Pristiq is manufactured by Pfizer.
Headquartered in Israel, Teva has a portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area.